BioReport (@bio_report) profile picture
Joined December 2014
Photo by BioReport (@bio_report)Photo by BioReport (@bio_report)Photo by BioReport (@bio_report)Photo by BioReport (@bio_report)Photo by BioReport (@bio_report)Photo by BioReport (@bio_report)Photo by BioReport (@bio_report)Photo by BioReport (@bio_report)Photo by BioReport (@bio_report)Photo by BioReport (@bio_report)
$CAPR so first the Lancet and now AHA gave them the pediatric heart research award. This on top of all investigators saying therapy should be approved. Sounds like FDA needs to re-look at what “failed” means in rare disease
1
23
900
Wow $VCYT sell off looks way overdone
5
556
$BCRX looks dirt cheap
1
2
453
Whole market held up by AI and $META one of the only companies showing clear growth from its utilization and investors still don’t like the investment. Makes little sense
210
Crazy $RCUS going to be down over 20% on an offering that allows them to get their blockbuster kidney drug to market. Already way undervalued
1
3
625
A bit odd to only see $GRAL reacting to FDA adcom and not the other big MCED players like $CAI $GH $FRNM who are behind Grail but seem to have better technologies.
3
3
1,240
$DKNG really think it’s misguided to think opening up the whole US to sports trading through prediction markets is bad for them
1
4
1,158
$AVAV really solid quarter
5
790
If you need a stock analyst to tell you $LMT is undervalued you shouldn’t be investing
1
3
355
$AVGO looking cheap based on those 2027 projections
283
The sell off in defense names has been brutal $LMT $NOC
1
1,001
$MYGN market cap under $300M is just crazy. I agree they need to really figure out path forward and it’s likely can’t be alone but I would argue that makes them even more valuable for investors.
3
328
$CAPR so turns out @adamfeuerstein was wrong and CEO was telling the truth. No CRL and no matter what games FDA plays with the data the skeletal muscle endpoint is statically significant.
5
5
1
68
34,903
Wow $GH ordered to pay a 6% royalty going forward on basically all their products and stock is only down 3%?
1
3
792
$BLLN quite the overreaction for a company growing 50% annually. Could see a 15% drop but almost 40% is crazy
5
810
$MYGN valuation is a joke at almost .3x revenue multiple. Would be so easy to turn this business highly profitable
1
2
1,116
$SIBN press release said raised guidance. They raised revenue guidance from $230M to $231M. That made me laugh
4
323
$MYGN execution has been horrendous but it’s surprising that valuation is giving zero consideration to sum of the parts value. If they were just a HCT business current market cap would be $800M+
1
1
387
$RDDT wow looks cheap. Everyone hanging onto a CEO comment even through they beat and raised guidance
311